1. Home
  2. MTSI vs UTHR Comparison

MTSI vs UTHR Comparison

Compare MTSI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MACOM Technology Solutions Holdings Inc.

MTSI

MACOM Technology Solutions Holdings Inc.

HOLD

Current Price

$280.69

Market Cap

20.1B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$493.30

Market Cap

23.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTSI
UTHR
Founded
1950
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.1B
23.1B
IPO Year
2011
1999

Fundamental Metrics

Financial Performance
Metric
MTSI
UTHR
Price
$280.69
$493.30
Analyst Decision
Strong Buy
Buy
Analyst Count
10
14
Target Price
$257.60
$567.57
AVG Volume (30 Days)
1.2M
466.3K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
13.07
EPS
2.52
13.07
Revenue
$967,258,000.00
$1,483,300,000.00
Revenue This Year
$23.55
$6.39
Revenue Next Year
$17.74
$14.18
P/E Ratio
$108.95
$37.81
Revenue Growth
32.58
2.38
52 Week Low
$122.30
$409.15
52 Week High
$418.90
$609.35

Technical Indicators

Market Signals
Indicator
MTSI
UTHR
Relative Strength Index (RSI) 53.17 40.37
Support Level $253.29 $492.57
Resistance Level $289.34 $538.77
Average True Range (ATR) 11.19 13.08
MACD 1.98 -0.04
Stochastic Oscillator 83.03 39.15

Price Performance

Historical Comparison
MTSI
UTHR

About MTSI MACOM Technology Solutions Holdings Inc.

MACOM Technology Solutions Holdings Inc is a provider of analog, digital, and mixed-signal semiconductor solutions to original equipment manufacturers and distributors. These solutions are found in systems for industrial, medical, scientific, and test and measurement markets. The firm's portfolio of products includes integrated circuits, multichip modules, power pallets and transistors, diodes, amplifiers, switches and switch limiters, passive and active components, and complete subsystems.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: